Projected 2018 sales: $6.598 billion
2012 sales: $3.767 billion
Celgene's ($CELG) blood cancer drug, a blockbuster with $3.77 billion in 2012 sales, is already a success at home. First approved in the U.S. in 2006, sales jumped 17% last year partly because patients stay on the drug for long periods of time. Now, it's taking its show on the road. In February, Revlimid scored an approval from Chinese regulators that comes with an import license, and the company expects to launch the drug there in the not-too-distant future.
Not that Revlimid is short on domestic revenue streams. The drug is approved in combination with dexamethasone in previously treated multiple myeloma patients and for patients with anemia caused by myelodysplastic syndromes. Additionally, in June, Revlimid was approved to treat rare blood cancer mantle-cell lymphoma; that use is expected to pad sales by up to $200 million.
But Celgene isn't stopping there. It's currently recruiting for new late-stage trials in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. And earlier this month, the company revealed late-stage data showing that Revlimid improved survival in patients with newly diagnosed multiple myeloma--for which the drug market has been forecast to grow 60% by 2021.
Special Report: Celgene: The house that Revlimid built - The Biggest R&D Spenders in Biotech
Deaths force Celgene to stop Revlimid CLL trial in its tracks
Celgene hits new bump in extending Revlimid sales
Celgene's hopes for Revlimid stymied by regulatory setback
Celgene wins China's blessing for Revlimid launch